Marsh, R. A., Rao, M. B., Gefen, A., Bellman, D., Mehta, P. A., Khandelwal, P., . . . Davies, S. M. (2015). Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. Biol Blood Marrow Transplant.
Citação norma ChicagoMarsh, Rebecca A., et al. "Experience With Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients With Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends On Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen." Biol Blood Marrow Transplant 2015.
Citação norma MLAMarsh, Rebecca A., et al. "Experience With Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients With Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends On Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen." Biol Blood Marrow Transplant 2015.